论文部分内容阅读
目的:探讨酶放大免疫法监测肾移植受者他克莫司谷浓度的情况及其对移植肾功能的影响。方法:回顾性分析酶放大免疫分析(EMIT)法监测159例肾移植受者术后2849例次他克莫司谷浓度的结果及肾移植术1个月后他克莫司谷浓度对血肌酐(Scr)的影响。结果:2 466例次(占总例次的86.5%)他克莫司谷浓度值处于参考值范围,低于下线及高于上线参考值的比例分别为6.3%、7.1%;肾移植术1个月后,当他克莫司谷浓度值小于5μg·L~(-1)或大于20μg·L~(-1)时,Scr值升高显著(P<0.05或0.01),当他克莫司谷浓度值小于5μg·L~(-1)或大于15μg·L~(-1)时,Scr异常值的比例显著增加。结论:用EMIT法监测他克莫司谷浓度值,药物浓度控制比较稳定,5～15μg·L~(-1)是相对安全的浓度范围。
Objective: To investigate the effect of Enzyme Immunoassay (IMRT) on monitoring the concentration of tacrolimus in renal transplant recipients and its effect on renal function. Methods: The results of 2849 cases of tacrolimus concentration monitored by enzyme-amplified immunoassay (EMIT) in 159 renal transplant recipients and the effect of tacrolimus concentration on serum creatinine (Scr) effects. Results: The tacrolimus concentration in 2666 cases (86.5% of the total cases) was within the range of reference value. The ratios below and above the baseline were 6.3% and 7.1%, respectively. Renal transplantation After 1 month, when the concentration of tacrolimus was less than 5μg · L -1 or more than 20μg · L -1, Scr increased significantly (P <0.05 or 0.01) When the concentration of MoSt was less than 5μg · L -1 or more than 15μg · L -1, the ratio of Scr abnormality increased significantly. Conclusion: The concentration of tacrolimus was monitored by EMIT method. The concentration of tacrolimus was stable. The concentration range of 5 ~ 15μg · L -1 was relatively safe.